ERBB2 and breast cancer: As shown in Table 1, the cohort is composed of 497 BC patients, representative of the distribution of molecular BC subtypes, with 79.5% Luminal A, 9.3% Luminal B, 3.4% HER2 and 7.9% TNBC.